Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug;103(8):e364-e367.
doi: 10.3324/haematol.2018.187773. Epub 2018 Mar 15.

Impact of age on genetics and treatment efficacy in follicular lymphoma

Stefan Alig  1 , Vindi Jurinovic  1   2 , Alessandro Pastore  3 , Deepak Bararia  1 , Sarah Häbe  1 , Johannes C Hellmuth  1   4 , Robert Kridel  5 , Randy Gascoyne  6   7 , Christian Schmidt  1 , Anna-Katharina Zöllner  1 , Christian Buske  8 , Martin Dreyling  1 , Michael Unterhalt  1 , Wolfgang Hiddemann  1   9 , Eva Hoster  1   2 , Oliver Weigert  10   9
Affiliations

Impact of age on genetics and treatment efficacy in follicular lymphoma

Stefan Alig et al. Haematologica. 2018 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Targeted mutational burden (TMB) by age. (A) TMB in all 74 genes depicted as a dotplot by age (Quasi-Poisson regression). Boxplots indicate median number of gene mutations with 1st and 3rd quartiles, whiskers represent 1.5× interquartile range. (B) TMB by mutually exclusive types of gene mutations. (C) Fraction of single nucleotide variants (SNV) with features of aberrant somatic hypermutation (aSHM): “WRCY” denotes mutations within this hotspot motif. “TSS <2kb” denotes mutations within 2kb from the transcriptional start sites. “Transitions” denotes transition mutations. “Targets of aSHM” denotes mutations within known target genes of aSHM (see Online Supplementary Methods). Error bars show standard error of the mean. Color legend: gray for 18-40 years; blue for >40-50 years; purple for >50-60 years; orange for >60-70 years; green for >70 years. SNV: single nucleotide variant; aSHM: aberrant somatic hypermutation; TSS: transcriptional start site; yr: year
Figure 2.
Figure 2.
Treatment outcome of GLSG2000 patients who received R-CHOP for advanced FL according to age cohorts. A) Age distribution and definition of distinct age cohorts. (B) Kaplan–Meier curves for overall survival (OS). (C) Kaplan–Meier curve for failure-free survival (FFS). (D) Cumulative incidence analysis of failure-free survival with progression of disease (POD; dashed lines) as primary event, and death w/o POD (solid lines) as competing event. Analyses for progression-free survival (PFS) analogous to C and D are shown in Online Supplementary Figure S4. (E) Cumulative incidence of death w/o POD by age group after a median follow up of 5.7 years (95%-CI [5.1;6.1]). Black bars indicate deaths w/o POD within the first year after treatment initiation, gray bars indicate deaths beyond one year. (F) Causes of death w/o POD in patients >70 years. Causes of deaths within the first year after treatment initiation are shown in darker colors, those occurring after the first year in lighter colors. Color legend: gray for 18-40 years; blue for >40-50 years; purple for >50-60 years; orange for >60-70 years; green for >70 years. POD: progression of disease; w/o: without; yr: year; cardiovasc. disease: cardiovascular disease
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265. - PubMed
    1. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562. - PubMed
    1. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–1122. - PubMed
    1. Weigert O, Weinstock DM. The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. Blood. 2012;120(13):2553–2561. - PubMed
    1. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–278. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources